Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation

New England Journal of Medicine

Volumn 359, Issue 2, 2008, Pages 158-165

  Hodgson Zingman, Denice M ^a   Karst, Margaret L ^b   Zingman, Leonid V ^a   Heublein, Denise M ^b   Darbar, Dawood ^b   Herron, Kathleen J ^b   Ballew, Jeffrey D ^b   De Andrade, Mariza ^c   Burnett Jr , John C ^b   Olson, Timothy M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP;

ACTION POTENTIAL; ADULT; AGED; ANIMAL TISSUE; ARTICLE; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; FEMALE; FRAMESHIFT MUTATION; HEART ATRIUM FIBRILLATION; HEART MUSCLE POTENTIAL; HETEROZYGOSITY; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT;

EID: 46949093558     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0706300     Document Type: Article

References (23)

1. Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
2. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6.
3. Fox CS, Parise H, D'Agostino RB, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-5.
4. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-7.
5. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997;336:905-11.
6. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003;41:2185-92.
7. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299: 251-4.
8. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005;293:447-54.
9. Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15: 2185-91.
10. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006;354:2677-88.
11. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-7.
12. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-8.
13. Sorbera LA, Morad M. Atrionatriuretic peptide transforms cardiac sodium channels into calcium-conducting channels. Science 1990;247:969-73.
14. Le Grand B, Deroubaix E, Couétil JP, Coraboeuf E. Effects of atrionatriuretic factor on Ca2+ current and Cai-independent transient outward K+ current in human atrial cells. Pflugers Arch 1992;421: 486-91.
15. Lonardo G, Cerbai E, Casini S, et al. Atrial natriuretic peptide modulates the hyperpolarization-activated current (If) in human atrial myocytes. Cardiovasc Res 2004;63:528-36.
16. Crozier I, Richards AM, Foy SG, Ikram H. Electrophysiological effects of atrial natriuretic peptide on t he cardiac conduction system in man. Pacing Clin Electro-physiol 1993;16:738-42.
17. Stambler BS, Guo GB. Atrial natriuretic peptide has dose-dependent, autonomi-cally mediated effects on atrial refractoriness and repolarization in anesthetized dogs. J Cardiovasc Electrophysiol 2005;16: 1341-7.
18. Chen HH, Lainchbury JG, Burnett JC Jr. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002;40:1186-91.
19. Johns DG, Ao Z, Heidrich BJ, et al. Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem Biophys Res Commun 2007;358: 145-9.
20. Kato T, Muraski J, Chen Y, et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005;115:2716-30.
21. Fatkin D, Otway R, Vandenberg JI. Genes and atrial fibrillation: a new look at an old problem. Circulation 2007;116: 782-92.
22. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27:47-72.
23. Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006;355:2003-11.